Leadership & Pay ·
Rani Therapeutics Holdings, Inc. appointed Michelle Gilson to its Board of Directors effective August 1, 2026
RANIRani Therapeutics Holdings, Inc.
Rani Therapeutics Holdings, Inc. appointed Michelle Gilson to its Board of Directors effective August 1, 2026. Ms. Gilson also assumed the role of Chair of the Audit Committee. She previously served as Chief Financial Officer of Arcellx, Inc., until its acquisition by Gilead Sciences in April 2026, and has extensive experience in biotechnology equity research and investment banking at firms including Canaccord Genuity, Jefferies, Nomura, Oppenheimer, and Goldman Sachs. The company entered into a standard indemnification agreement with Ms. Gilson. Rani Therapeutics Holdings, Inc. operates in the pharmaceutical industry, developing therapies for rare diseases.